CrystalGenomics Inc
KOSDAQ:083790
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CrystalGenomics Inc
Additional Paid In Capital
CrystalGenomics Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CrystalGenomics Inc
KOSDAQ:083790
|
Additional Paid In Capital
₩54.1B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-9%
|
|
|
Celltrion Inc
KRX:068270
|
Additional Paid In Capital
₩14.2T
|
CAGR 3-Years
154%
|
CAGR 5-Years
77%
|
CAGR 10-Years
36%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Additional Paid In Capital
₩323.4B
|
CAGR 3-Years
29%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Additional Paid In Capital
₩241.6B
|
CAGR 3-Years
40%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Additional Paid In Capital
₩149.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
3%
|
CAGR 10-Years
18%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Additional Paid In Capital
₩543B
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
CrystalGenomics Inc
Glance View
CrystalGenomics, Inc. engages in the discovery and development of novel therapeutics. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2006-01-06. The firm operates its business through four segments. The Drug Substance Manufacturing segment manufactures and sells drug substances such as anti-inflammatory analgesics, antispasmodics, and asthma treatments. The Finished Drug Manufacturing segment produces and supplies finished drugs such as cephalosporin antibiotics. The Pharmaceutical Research and Development segment is engaged in the provision of clinical trial analysis and technical services, and sales of new drugs. The company also engages in real estate rental business. The Other segment is engaged in the manufacture and sale of hot pats and other household goods.
See Also
What is CrystalGenomics Inc's Additional Paid In Capital?
Additional Paid In Capital
54.1B
KRW
Based on the financial report for Dec 31, 2025, CrystalGenomics Inc's Additional Paid In Capital amounts to 54.1B KRW.
What is CrystalGenomics Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
-9%
Over the last year, the Additional Paid In Capital growth was 1%. The average annual Additional Paid In Capital growth rates for CrystalGenomics Inc have been -23% over the past three years , -16% over the past five years , and -9% over the past ten years .
